ReviewFrontiers in pharmacology2025
Target fishing: from "needle in haystack" to "precise guidance"--new technology, new strategy and new opportunity.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug target discovery is the core breakthrough point of new drug research and development. The chemical complexity and biological network regulation characteristics of natural product systems with a long history of clinical application pose a challenge to the traditional single-target research paradigm. Although traditional technologies based on molecular docking and chemical probes are still dominant, breakthroughs in disruptive technologies such as artificial intelligence and deep learning are driving the transformation of research methods from 'broad-spectrum screening' to 'precise capture'. This review systematically discusses the latest progress of drug target capture technology. Studies have shown that the deep integration of deep learning and knowledge graph not only significantly improves the accuracy of target prediction, but also constructs an interdisciplinary collaboration network across chemical informatics, systems biology and clinical medicine. The fusion of this technology shows three core advantages: multi-dimensional drug-target interaction analysis ability based on deep representation learning; integrate the dynamic predictive modeling ability of multi-omics data; and the interpretable decision support ability with clinical transformability. The purpose of this paper is to provide a theoretical framework for the academic community, and to build a bridge from basic research to clinical application, so as to promote the development of precision drugs into a new era of intelligent drive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.